Accelerate to discover

Back to filter

Related topics

Intoducing cellenONE: The revolutionary Single Cell isolator

Cellenion

May 25, 2022

A revolutionary platform based on sciDROP PICO precision dispensing technology and coupled with advanced image...

Advances in Leukemia research using shear flow and Bioflux system

Fluxion Biosciences

May 24, 2022

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...

Extracellular Vesicle Purity Enhanced by Gen 2 qEV Columns With Customised Proprietary Resin

IZON

May 4, 2022

Izon Science has announced the launch of Gen 2, the enhanced range of qEV columns for size-exclusion...

Why use Cytek Aurora?

Cytek Biosciences

May 3, 2022

A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...

May 28, 2022

In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers

MOLECUBES

Mar 9, 2022

Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...

Introducing IsoPlexis Single-Cell Natural Killer Panel

IsoPlexis

Mar 4, 2022

Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...

Enhanced small particle detection on CytekAurora and Northern Lights

Cytek Biosciences

Mar 2, 2022

Aurora system with ESP option, can fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...

May 28, 2022

Multi-modal PET drives interdisciplinary preclinical imaging

Bruker Biospin

Feb 23, 2022

Preclinical imaging (PCI) plays a vital role in understanding the biological processes behind disease states at the...

Show all topics (10)

Differentation displacement in acute myeloid leukemia through enhancer activation

Aug 7, 2018

LSD1 is a flavin adenine dinucleotide (FAD)-dependent homolog of the amine oxidase family and there was recently brought attention to it as a potential therapeutic target. The interest came from an observation of unusually high expression of LSD1 in certain types of poor-prognosis cancers. It was previously thought that LSD1 removes monomethyl and dymethyl histone marks. However, recently it was showed that it interacts with multiple transcripton factor. This raised a possibility of other drugs being used.

New inhibitor ORY-1001 was succesfully tested on LSD1 and blast cell differentioation was observed. The flow cytometric testing on this experiment was done with Novocyte. ORY-1001 disrupts the protein interaction between LSD1 and GFI1.

Scientific paper
Application

Related technologies: Conventional flow cytometry

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

The most advanced benchtop flow cytometer on the market

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey